ClinicalTrials.gg
RecruitingNCT05841199VT flowUpdated Mar 27, 2026

Coronary Flow During Rapid Heart Rates

An observational study in Ventricular Tachycardia, Coronary Artery Disease and Heart Failure, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Imperial College London · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Tachycardia, Ventricular with a site in United Kingdom — 12 open to participants now, 14 under way, none of them phase 3. Tachycardia, Ventricular · United Kingdom.

Planned enrollment
8th of 14
70 · median 98
Started
2023
with 2 others
Observational
14 of 38
6 open now
Primary completion
2026-06
later than 4 of 13 live
Registered
30th of 38
by date
Lead sponsor
2 of 38
Imperial College London

Among the 38 studies in Tachycardia, Ventricular with a site in United Kingdom, this one is the 8th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2023, is one of 14 observational ones, reaches primary completion later than 4 of the 13 other live ones, and was the 30th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

12 of the 38 studies in Tachycardia, Ventricular with a site in United Kingdom are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Tachycardia, Ventricular with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this observational study is to learn about the factors which determine how well ventricular tachycardia (VT) is tolerated. The main questions it aims to answer are:

  1. What impact does coronary artery disease have on the ability for a patient to tolerate VT?
  2. Does treatment of coronary artery disease with stents improve the tolerability of VT?

Participants who are undergoing a clinically indicated coronary angiogram or coronary angioplasty procedure will have measurements of blood pressure, coronary pressure and coronary flow made during pacing at a range of heart rates.

Read the detailed description

Ventricular tachycardia (VT) is a common and life-threatening arrhythmia that occurs in people with heart problems. Some patients who develop this arrhythmia remain very stable with very little symptoms while others become unstable with low blood pressure or even sudden death. It is not known why some people tolerate the arrhythmia well and others do not.

If VT is not tolerated then current practice is to offer an implantable cardioverter defibrillator (ICD) which can deliver a shock to the heart if dangerous heart rhythms are detected. While shocks can be life-saving, they are also harmful, including causing psychological distress. ICDs also frequently deliver shocks when they are not needed.

If research could identify which factors predispose a person to be stable or unstable in VT, this would allow doctors to help them in a range of ways. One way would be to treat patients to improve the tolerance of VT, so avoiding the need for an ICD. Another would be to assess the the risk of instability and so allow a patient-centred decision on whether an ICD is needed.

In this study the investigators plan to recruit patients who are referred for a coronary angiogram. During the angiogram, the investigators will stimulate the heart at a range of fast heart rates and measure their blood pressure and flow in their coronary arteries. In patients who undergo stenting for a coronary stenosis, the investigators will also make these measurements after stenting so they can see if there is any difference. By recruiting a range of different cardiology patients, the investigators will be able to assess which factors contribute to stability during VT.

03

Conditions studied

  • Ventricular Tachycardia
  • Coronary Artery Disease
  • Heart Failure
  • Coronary Microvascular Dysfunction
  • Coronary Microvascular Disease

Keywords

  • Ventricular Tachycardia
  • Coronary Artery Disease
  • Heart Failure
  • Coronary Microvascular Dysfunction
  • Coronary Microvascular Disease
  • Percutaneous Coronary Intervention
  • Implantable Cardioverter Defibrillator
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults referred for coronary angiography or coronary angioplasty.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to give valid consent
  • Referred for coronary angiography or coronary angioplasty
  • Suitable for percutaneous physiological interrogation and PCI when clinically indicated

Exclusion criteria

Exclusion Criteria:

  • Unable to give valid consent
  • Pregnant or breastfeeding women
  • Unstable coronary artery disease (acute coronary syndrome)
  • Severe multivessel coronary artery disease suitable for coronary artery bypass grafting
  • Severe heart valve disease
  • Severe ( IV) heart failure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Controls

    10 patients with unobstructed coronary arteries, normal microvascular function and normal LV function.

    Diagnostic Test: Pressure and flow measurement during simulated VT

  • Coronary artery disease

    25 patients with severe, single-vessel coronary artery disease of the proximal LAD or proximal other dominant vessel awaiting PCI.

    Diagnostic Test: Pressure and flow measurement during simulated VT

  • Microvascular dysfunction

    15 patients with without severe disease in any coronary artery, impaired microvascular function and normal LV function.

    Diagnostic Test: Pressure and flow measurement during simulated VT

  • Heart failure

    20 patients with LV systolic dysfunction (LVEF\<40%).

    Diagnostic Test: Pressure and flow measurement during simulated VT

Interventions

  • Diagnostic testPressure and flow measurement during simulated VT

    Participants undergoing coronary angiography will have measurements of blood pressure, coronary pressure and coronary flow during simulated VT. VT will be simulated using pacing at a range of heart rates.

06

What researchers measure

Primary outcomes

  1. Change in coronary flow in participants with different levels of coronary microvascular function.

    Time frame: At baseline and during simulated VT

  2. Change in coronary flow in participants immediately before and after PCI

    Time frame: At baseline and during simulated VT, immediately before PCI and after PCI

  3. Change in blood pressure in participants with different levels of coronary microvascular function.

    Time frame: At baseline and during simulated VT

  4. Change in blood pressure in participants before and after PCI

    Time frame: At baseline and during simulated VT, immediately before PCI and after PCI

Secondary outcomes

  1. Change in coronary flow in participants with different levels of left ventricular function

    Time frame: At baseline and during simulated VT

  2. Change in blood pressure in participants with different levels of left ventricular function

    Time frame: At baseline and during simulated VT

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jun 2026, 34 months after the start.

Of 69 observational studies under Tachycardia, Ventricular, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 108. This study's planned 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2023
First posted
May 3, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Jun 2, 2026
CompletionEst.
Jun 2, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05841199
Responsible party
Sponsor
First posted
May 3, 2023
Start date
Aug 1, 2023
Primary completion
Jun 2, 2026 (estimated)
Completion
Jun 2, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

Rahul Bahl
Contact
r.bahl@imperial.ac.uk
+44 20 7594 1093
Ricardo Petraco
Contact
r.petraco@imperial.ac.uk
+44 20 7594 1093
Ricardo Petraco
principal investigator · Senior Clinical Research Fellow

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion